Berberine vs MOTS-c
Moderate Research vs Well Studied
monitor Researched · 90% Both are AMPK activators; monitor for additive effects.
Molecular Data
Berberine MOTS-c
Weight 336.36 Da 2,174.6 Da
Half-life ~4 hours ~30 minutes
Chain — 16 amino acids
Type Isoquinoline alkaloid (C20H18NO4+) Mitochondrial-derived peptide (MDP)
Key Benefits
Berberine
01 Activation of AMPK, improving cellular energy metabolism and glucose utilization
02 Clinically demonstrated reductions in fasting blood glucose and HbA1c comparable to metformin in some trials
03 Improved lipid profiles with reductions in total cholesterol, LDL cholesterol, and triglycerides
04 Enhanced insulin sensitivity through upregulation of insulin receptor expression
05 PCSK9 inhibition leading to improved LDL cholesterol clearance
06 Gut microbiome modulation favoring beneficial short-chain fatty acid-producing bacteria
07 Anti-inflammatory effects via NF-kB pathway suppression
08 Available over the counter as a dietary supplement without prescription
MOTS-c
01 Enhanced insulin sensitivity (~30% improvement)
02 Improved glucose metabolism and tolerance
03 AMPK pathway activation
04 Mitochondrial function optimization
05 Exercise performance enhancement (12-15% improvement)
06 Potential lifespan extension (6.4% median increase in mice)
Dosing Protocols
Berberine
500 mg 2-3x/day / 2-3x daily with meals
MOTS-c
Start 5mg daily, increase to 10-15mg based on goals / Daily for metabolic support, or 3x weekly for anti-aging
Metabolic health 5-10mg Once daily
Anti-aging protocol 15mg 3x weekly
Exercise performance 10-15mg Pre-workout
Conservative start 5mg Once daily
Side Effects
Berberine
Gastrointestinal distress (diarrhea, cramping, bloating, nausea, flatulence) - most frequent complaint, affecting 10-15% of users, especially at higher doses or without food
Constipation (less common than diarrhea but reported by some users)
Decreased appetite
Mild abdominal discomfort, particularly during the first 1-2 weeks of use
MOTS-c
Generally well-tolerated in animal studies with minimal side effects
Mild injection site reactions (redness, swelling)
Contraindications
Pregnancy and breastfeeding (berberine may stimulate uterine contractions and crosses into breast milk)
Neonates and young children (risk of kernicterus - berberine can displace bilirubin from albumin)
Severe hepatic impairment
Concurrent use with medications that have narrow therapeutic indices metabolized by CYP3A4 (e.g., cyclosporine, tacrolimus) without close medical supervision
Known hypersensitivity to berberine or berberine-containing plants
Pregnancy or breastfeeding
WADA prohibited substance (banned for athletic competition)
Limited long-term human safety data
Research Evidence
Berberine MOTS-c
Status Moderate Research Well Studied
References 5 studies 5 studies
Latest 2023 August 2025
FDA Approved No No
More comparisons: MK-677
This comparison is for educational and research purposes only. Consult a healthcare professional before use.